Cooperative Agreement W81XWH1920060

This U01AI187033 Cooperative Agreement award from the National Institutes of Health (CFDA 93.310 Trans-NIH Research Support program) provides $552,787 in funding to Old Dominion University to develop YK-4-250, a novel radiation mitigator targeted to the AT1 receptor for treating gastrointestinal acute radiation syndrome (GI-ARS). The research aims to investigate the mechanisms by which YK-4-250 can mitigate GI toxicity and mortality following exposure to ionizing radiation. Key objectives...

The U.S. National Institutes of Health (NIH), through the Trans-NIH Research Support program (CFDA 93.310), awarded a $593,823 Cooperative Agreement to Albert Einstein College of Medicine for the development of a thrombopoietin mimetic (TPOM) as a medical countermeasure for gastrointestinal acute radiation syndrome (GI-ARS). The project aims to further develop TPOM, a synthetic, pegylated peptide that binds to the thrombopoietin receptor, to mitigate GI-ARS by stimulating the regeneration of...

This Cooperative Agreement award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $470,309 to Chromologic LLC for the development of a genetically modified probiotic that can deliver a therapeutic cytokine (INF-β) to the gastrointestinal (GI) tract. The goal is to use this orally administered probiotic to mitigate radiation-induced hematopoietic and GI injury, improving survival from 0-10% to 70-80% after exposure to high levels...

This federal Cooperative Agreement award, issued by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), provides $597,518.00 in funding to the Sloan-Kettering Institute for Cancer Research in New York, NY. The award supports research to develop an anti-ceramide antibody as a mechanism-based approach to mitigate gastrointestinal acute radiation syndrome (GI-ARS) and delayed effects of acute radiation exposure (DEARE). The...

This federal Cooperative Agreement award, provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), aims to develop predictive biomarker panels for assessing the risk of delayed radiation-induced lung and kidney injuries. The $570,849 grant, awarded on May 19, 2025, will fund the development of "LungWatch" and "KidneyWatch" multi-omics assays and companion software to enable risk assessment and early therapeutic...

The U.S. National Institutes of Health (NIH) Office of the Director awarded a $515,326 Cooperative Agreement under the Trans-NIH Research Support program (CFDA 93.310) to Duke University to develop novel mitigators of gastrointestinal acute radiation syndrome (GI-ARS). The research aims to promote the regeneration of irradiated intestinal epithelium by targeting the cGAS-STING-Clusterin axis. Key objectives include defining the mechanisms by which Clusterin mitigates GI-ARS and dissecting the...

This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to SRI International provides $401,125 in funding to quantify the association between genetic factors and radiation sensitivity in cancer patients. The research aims to identify germline genetic variants and gene expression patterns that contribute to individual differences in radiation response. The goal is to develop a predictive screening platform to optimize radiation dosing and mitigate...

This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...

The National Institutes of Health (NIH) awarded a $239,363 Project Grant under the Research Infrastructure Programs (CFDA 93.351) to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. The grant aims to determine the radioprotective efficacy of dietary administration of highly radiation-resistant non-pathogenic fungi in the Drosophila model system. The research will evaluate if consumption of these fungal strains can increase resistance to acute radiation damage across...

The National Cancer Institute (NCI) awarded a $898,497 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Radiopharmaceutical Imaging and Dosimetry, LLC to develop a cloud-based, customer-responsive dosimetry tool for alpha-particle emitting radiopharmaceutical therapies. The key objectives are to: 1) establish a library of microscale S-values and apportionment factors for dose-limiting tissues, 2) implement a macro-to-micro dosimetry methodology to enable...